Abstract:Proteolysis-targeting chimera (PROTAC) is an attractive technology in drug discovery. Canonically, targets act as a basic starting point in the most previous PROTAC design. Here, we designed degraders considering from the view of clinical benefits. With this novel design, Brigatinib was turned into a degrader SIAIS164018 and endowed with unique features. First, SIAIS164018 could degrade not only ALK fusion proteins in activating or G1202R-mutated form but also mutant EGFR with L858R + T790M, which are two most important targets in non-small-cell lung cancer. Second, SIAIS164018 strongly inhibited cell migration and invasion of Calu-1 and MDA-MB-231. Third and surprisingly, SIAIS164018 degrades several important oncoproteins involved in metastasis such as FAK, PYK2, and PTK6. Interestingly, SIAIS164018 reshuffled the kinome ranking profile when compared to Brigatinib. Finally, SIAIS164018 is orally bioavailable and well tolerated in vivo. SIAIS164018 is an enlightening degrader for us to excavate the charm of protein degradation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00373?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00373</a>.NMR and HPLC of compounds <b>1–12</b>; hook effect of SIAIS164018; signaling pathway; apoptosis analysis; gene ontology analysis; maximal tolerance dose study; AlK mutant identification; kinome map; and degradation through UPS (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00373/suppl_file/jm1c00373_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00373/suppl_file/jm1c00373_si_002.csv">CSV</a>)Proteomics data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00373/suppl_file/jm1c00373_si_003.xlsx">XLSX</a>)RNA-seq data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00373/suppl_file/jm1c00373_si_004.xlsx">XLSX</a>)Kinome data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00373/suppl_file/jm1c00373_si_005.xlsx">XLSX</a>)This article has not yet been cited by other publications.

Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders

Structure-based Rational Design Enables Efficient Discovery of a New Selective and Potent AKT PROTAC Degrader.

Structure-Based Rational Design Enables Discovery of a New Selective and Potent Akt Degrader with Improved Dermatologic Safety

Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (protacs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells.

Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.

Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders

Design, synthesis, and biological evaluation of Wee1 kinase degraders

Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile

Development Of Alectinib-Based Protacs As Novel Potent Degraders Of Anaplastic Lymphoma Kinase (Alk)

Design, synthesis and biological evaluation of a novel PAK1 degrader for the treatment of triple negative breast cancer

Design, Synthesis, and Biological Evaluation of Proteolysis-Targeting Chimeras as Highly Selective and Efficient Degraders of Extracellular Signal-Regulated Kinase 5

Discovery of the First Potent DYRK2 Proteolysis Targeting Chimera Degraders

Discovery of Novel KSP-targeting PROTACs with Potent Antitumor Effects in Vitro and in Vivo

Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS G12D

Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation

Design, Synthesis, and Antitumor Activity Evaluation of Proteolysis-Targeting Chimeras as Degraders of Extracellular Signal-Regulated Kinases 1/2

Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B

Design, Synthesis and Biological Evaluation of KRASG12C-PROTACs.

Phthalimide Conjugations for the Degradation of Oncogenic PI3K

Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the Ataxia telangiectasia and RAD3-related (ATR) kinase

Design and synthesis of selective degraders of EGFR L858R/T790M mutant.